S2 Ep18: #29 Hallucinogens with Dr. Al Garcia-Romeu
Aug 15, 2024
auto_awesome
In this discussion, Dr. Al Garcia-Romeu, a prominent researcher at the Johns Hopkins Center for Psychedelic and Consciousness Research, sheds light on the transformative potential of hallucinogens. He delves into their mechanisms of action, focusing on psilocybin and its role in treating addiction and mental health disorders. Risks of unregulated use and the intricacies of psychedelic-assisted therapy are explored, alongside the legal landscape affecting these substances. The conversation emphasizes informed patient communication and the importance of ongoing research in this emerging field.
Psychedelic-assisted therapy offers a structured, safe approach to treating mental health issues like addiction and depression.
Psychedelics, particularly psilocybin, have shown promise in rapidly improving mood and providing lasting effects for treatment-resistant depression.
The legal status of psychedelics poses challenges for research and safe usage, necessitating caution in sourcing and consumption.
Deep dives
Introduction to Psychedelic-Assisted Therapy
Psychedelic-assisted therapy is emerging as a promising approach for treating various mental health conditions, particularly addiction and depression. This therapeutic process contrasts with recreational drug use, as it incorporates a structured framework designed for safety and efficacy. Preparation for such therapy involves thorough psychological assessments to ensure candidates are suitable and that risks are known. The model emphasizes the importance of building a supportive therapeutic relationship, which aids clients in navigating challenging experiences during treatments.
Mechanisms of Action and Therapeutic Effects
Psychedelics, particularly psilocybin, operate primarily through serotonin receptor effects, offering rapid improvements in mood for individuals with conditions like major depressive disorder. Evidence highlights that high-dose psilocybin can provide long-lasting antidepressant effects, often lasting weeks or months after treatment. This benefit is especially significant for individuals experiencing treatment-resistant depression or existential distress related to serious illness. Current studies indicate that these effects can also extend into therapy for substance use disorders, showcasing the potential of psychedelics as adjuncts in addressing addiction.
Challenges and Considerations in Microdosing
Microdosing psychedelics has gained popularity, with enthusiasts believing it can enhance mental well-being. However, rigorous research on the effects and benefits of microdosing remains limited, leading many experts to question its efficacy, often attributing positive outcomes more to placebo effects. Concerns regarding the health implications of frequent microdosing persist, particularly regarding potential cardiovascular issues tied to long-term serotonin receptor activation. Consequently, understanding the parameters and expectations for both high-dose and microdosing experiences will be crucial for future exploration.
Legal and Safety Considerations
Legal status presents a significant barrier to the controlled use of psychedelics, as they remain classified as Schedule I substances under federal law in the United States. Despite some jurisdictions beginning decriminalization efforts, unauthorized use can result in severe consequences, including legal penalties and the risk of harmful, unregulated products. Users must be cautious about sourcing psychedelics, as street or commercial products may contain unknown or dangerous substances. Awareness of these legal and health risks is essential for any discussions surrounding psychedelic use.
Future Directions in Psychedelic Research
Research into psychedelics is rapidly evolving, with promising studies hinting at the potential for FDA approvals, particularly for MDMA in treating PTSD and psilocybin for depression. Early-phase clinical trials indicate that these substances may form a significant part of therapeutic regimens for resistant conditions. However, rigorous clinical research and monitoring will be necessary to fully understand their roles, safety, and effective integration within treatment practices. Continued dialogue and engagement with healthcare providers can help optimize treatment protocols, ensuring that psychedelics are introduced safely while remaining grounded in scientific evidence.
From Recreational Use to Possible Therapeutic Interventions
Learn how different hallucinogens act in the body and common dosing strategies. Appreciate the risks of use and the current state of hallucinogen research. We are joined in this episode by Dr. Albert Garcia-Romeu (Johns Hopkins Center for Psychedelic and Consciousness Research)
Claim CME for this episode at curbsiders.vcuhealth.org!
By listening to this episode and completing CME, this can be used to count towards the new DEA 8-hr requirement on substance use disorders education.
